false000072838700007283872025-03-032025-03-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 03, 2025

 

 

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-33407

41-1458152

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

c/o Perspective Therapeutics, Inc.

2401 Elliott Avenue

Suite 320

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

CATX

 

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

On March 3, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Corporate Presentation.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PERSPECTIVE THERAPEUTICS, INC.

 

 

 

 

Date:

March 4, 2025

By:

/s/ Juan Graham

 

 

 

Juan Graham, Chief Financial Officer

 

Slide 1

Corporate Presentation

Slide 2

 

Slide 3

Developing the Next Generation of Targeted Therapies

Slide 4

 

Slide 5

Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

Slide 6

 

Slide 7

Perspective’s Innovative Platform

Slide 8

Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window

Slide 9

 

Slide 10

Proposed Mechanism of Action for 212Pb

Slide 11

Perspective’s Proprietary Chelator Has Been Optimized for Lead-Based RPTs

Slide 12

 

Slide 13

 

Slide 14

Perspective’s Pre-Targeting Platform

Slide 15

Supply Chain and Manufacturing Infrastructure

Slide 16

On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products

Slide 17

 

Slide 18

Neuroendocrine Tumors: VMT-⍺-NET

Slide 19

 

Slide 20

 

Slide 21

 

Slide 22

Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

Slide 23

Anti-Tumor Activity

Slide 24

Signal of Sustained Anti-Tumor Activity

Slide 25

[212Pb]VMT-α-NET Was Well Tolerated

Slide 26

No Decline in Renal Function Observed

Slide 27

 

Slide 28

Patient with PR after [212Pb]VMT-α-NET

Slide 29

Melanoma Program: VMT01/02

Slide 30

 

Slide 31

 

Slide 32

 

Slide 33

 

Slide 34

Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma

Slide 35

 

Slide 36

Treatment Emergent Adverse Events (occurring in ≥ 2 patients and/or Grade ≥ 2)

Slide 37

 

Slide 38

 

Slide 39

 

Slide 40

 

Slide 41

 

Slide 42

PSV359 is Active Against FAP-α Expression on Tumor and on Stroma

Slide 43

 

Slide 44

 

Slide 45

 

Slide 46

General Corporate Information

Slide 47

 

Slide 48

 

Slide 49

 

Slide 50

 

Slide 51

Abbreviations

v3.25.0.1
Document And Entity Information
Mar. 03, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 03, 2025
Entity Registrant Name Perspective Therapeutics, Inc.
Entity Central Index Key 0000728387
Entity Emerging Growth Company false
Entity File Number 001-33407
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 41-1458152
Entity Address, Address Line One c/o Perspective Therapeutics, Inc.
Entity Address, Address Line Two 2401 Elliott Avenue
Entity Address, Address Line Three Suite 320
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98121
City Area Code (206)
Local Phone Number 676-0900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol CATX
Security Exchange Name NYSEAMER
Perspective Therapeutics (AMEX:CATX)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Perspective Therapeutics.
Perspective Therapeutics (AMEX:CATX)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Perspective Therapeutics.